PRNewsWire
28 Apr 2026, 01:32 UTC · 26w ago
Verdict
Headline leans bearish. We score GOSS −1.00.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
Which stocks this story touches
More negative than 99% of ticker scores this week
The company faces a Phase 3 trial failure, an 80% stock price collapse, and a securities class action lawsuit.
More positive than 53% of ticker scores this week
The article mentions the 'highly successful' STELLAR study for sotatercept as a benchmark for efficacy.
Continue reading
5 related stories
More negative than 99% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 32% of relationship scores this week
[mutual] Both companies are developing therapeutics (seralutinib and sotatercept) for the treatment of pulmonary arterial hypertension (PAH).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
15h ago
−60.8%
Price agrees with the score
$10.92 vs $27.88 close before publication (Apr 27) · not market-adjusted
GOSS chart →
